Foghorn Therapeutics Inc. (FHTX) SEC Filings & Earnings Calls

Clinical failure of FHD-909 and end of Lilly collaboration reduces pipeline value.

“decision not to advance the clinical trial of FHD-909 into the expansion phase” · word for word

Workforce reduction may impact morale and execution on remaining programs.

“reduction in its workforce by approximately 40%” · word for word

No product revenue; history of losses

“We do not have any products approved for sale and have not generated any revenue from product sales.” · word for word

Need for substantial additional funding

“We will need substantial additional funding to support our continuing operations and pursue our growth strategy.” · word for word

Clinical and regulatory uncertainties

“Our ability to generate any product revenue or product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more product candidates.” · word for word

Tariff and inflation impact on operating costs

“experience significant operating cost increases as a result of increased inflation or increased tariffs” · word for word

CBPd-171 program delay due to third-party CRO operational issue; updated guidance pending.

“CBPd-171 timeline has been delayed due to an unexpected operational issue at a third-party contract research organization supporting the in vivo animal models.” · word for word

Going concern / capital need

“We have incurred significant operating losses since our inception. For the three months ended March 31, 2026 and the year ended December 31, 2025, we reported net losses of $19.9 million and $74.3 million, respectively. As of March 31, 2026, we had an accumulated deficit of $652.3 million.” · word for word

No approved products / no product revenue

“We do not have any products approved for sale and have not generated any revenue from product sales.” · word for word

Clinical-stage biotech with no approved products; reliance on pipeline success.

“Clinical-stage biotechnology company; no revenue from product sales.”

Dependence on collaboration with Lilly for lead program.

“FHD-909 developed in collaboration with Lilly; 50/50 U.S. co-development agreement.”

No approved products / no product revenue

“We do not have any products approved for sale and have not generated any revenue from product sales.”

Going concern / capital need

“We have incurred significant operating losses since our inception. For the three months ended March 31, 2026 and the year ended December 31, 2025, we reported net losses of $19.9 million and $74.3 million, respectively. As of March 31, 2026, we had an accumulated deficit of $652.3 million.”

No approved products and early-stage pipeline

“We have a limited operating history and have no products approved for commercial sale” · word for word

Significant accumulated deficit and ongoing losses

“As of December 31, 2025, we had an accumulated deficit of $632.5 million.” · word for word

Need for substantial additional funding

“We will need substantial additional funding. If we are unable to raise capital when needed or under acceptable terms, we could be forced to delay, reduce or eliminate our research and product development programs or future commercialization efforts.” · word for word

Dependence on key personnel and third parties

“We are highly dependent on Adrian Gottschalk, our Chief Executive Officer.” · word for word

Intellectual property risks

“If we are unable to adequately protect our proprietary technology and platform or obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours” · word for word

Clinical-stage biotech with no approved products; pipeline risk

“All programs are in preclinical or early clinical stages; no revenue from product sales”

Dependence on collaboration with Lilly for lead program

“FHD-909 is developed in collaboration with Lilly; 50/50 U.S. co-development and co-commercialization agreement”

Equity offering will dilute existing shareholders.

“Form of Series Warrant and Pre-Funded Warrant included as exhibits.”

All pipeline programs are pre-commercial; no approved products; revenue depends on collaboration milestones.

“Pipeline table shows all programs in discovery, pre-clinical, or Phase 1; no approved products.”

Going concern risk

“The Company has incurred recurring losses, including net losses of $52.6 million and $67.1 million for the nine months ended September 30, 2025 and 2024, respectively. As of September 30, 2025, the Company had an accumulated deficit of $610.8 million. The Company expects to continue to generate operating losses in the foreseeable future.” · word for word

Financing risk

“The Company will need to obtain additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements to continue to fund its operations. The Company may not be able to obtain financing on acceptable terms, or at all.” · word for word

Clinical development risk

“There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be maintained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable.” · word for word

CFO departure creates leadership gap during critical pipeline execution phase

“CFO resigning effective Nov 14, 2025; search for replacement commenced.”

Clinical-stage company with no approved products; pipeline risk

“All programs are preclinical or Phase 1; no revenue from product sales.”